EPS for IntelliPharmaCeutics International Inc. (IPCI) Expected At $0.01

September 17, 2017 - By Nellie Frank

 EPS for IntelliPharmaCeutics International Inc. (IPCI) Expected At $0.01

Analysts expect IntelliPharmaCeutics International Inc. (TSE:IPCI) to report $0.01 EPS on October, 12.They anticipate $0.10 EPS change or 111.11 % from last quarter’s $-0.09 EPS. T_I’s profit would be $309,167 giving it 30.00 P/E if the $0.01 EPS is correct. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -112.50 % EPS growth. The stock increased 1.69% or $0.02 on September 15, reaching $1.2. About 6,400 shares traded. IntelliPharmaCeutics International Inc. (TSE:IPCI) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Intellipharmaceutics International Inc is a Canada pharmaceutical firm engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has market cap of $37.10 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular.

More notable recent IntelliPharmaCeutics International Inc. (TSE:IPCI) news were published by: Seekingalpha.com which released: “IntelliPharmaCeutics International: Great Opportunity, But Not Right Now” on March 17, 2017, also Globenewswire.com with their article: “Intellipharmaceutics Announces Resignation of Chief Financial Officer” published on August 08, 2017, Globenewswire.com published: “Intellipharmaceutics Intends to Vigorously Defend Recently Filed Purported …” on July 31, 2017. More interesting news about IntelliPharmaCeutics International Inc. (TSE:IPCI) were released by: Seekingalpha.com and their article: “IntelliPharmaCeutics International – Very Low Downside And Huge Upside” published on July 25, 2017 as well as Seekingalpha.com‘s news article titled: “IntelliPharmaCeutics International Has Huge Upside With Limited Downside” with publication date: November 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.